# Eli Lilly & Co.

Type: Company (LLY)

Source: GetYourBrief — https://getyourbrief.com/entity/eli-lilly-co
Canonical HTML page: https://getyourbrief.com/entity/eli-lilly-co

## Recent coverage (3 stories, network-wide)

### CareDx +35% on Medicare Win; Atai +33% on $3.8B Lilly Deal
2026-08-05 07:28:34 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 2

CareDx surged 35% after Medicare finalized coverage for transplant rejection tests, unlocking a major revenue opportunity. AtaiBeckley soared 33% following Eli Lilly's $3.8B acquisition, while Abbott raised its outlook and Apollomics extended its weekly rally to over 60% on its cancer drug candidate.
Full story: https://getbiobrief.com/story/caredx-atai-abbott-biotech-gainers-2026

### S&P 500 Marks Second Losing Week in 13 as AI Wreck Overwhelms Broad Market Gains
2026-06-28 12:17:51 · Sector: finance · Sentiment: Negative · Impact: 6/10 · Sources: 15

Despite nearly 66% of S&P 500 stocks climbing, the index posted its second losing week in 13 as heavy selling in AI megacaps like Micron completely negated the broad market rally. Oil prices dropped to pre-Iran crisis levels, boosting transportation and healthcare stocks, while Eli Lilly soared 7.1% on European drug approvals.
Full story: https://getfinancebrief.com/story/sp500-losing-week-ai-drag-june-2026

### Micron Drops 6.7% as AI Stock Sell-off Drags S&P to Second Losing Week
2026-06-28 12:17:40 · Sector: ai · Sentiment: Negative · Impact: 6/10 · Sources: 15

Artificial intelligence stocks faced intense selling pressure on June 26, with Micron Technology plunging 6.7% despite its stock roughly quadrupling this year, highlighting growing investor skepticism about the sustainability of AI-driven valuations. The broad sell-off in AI names single-handedly dragged the S&P 500 to its second losing week in 13, even as most other stocks rose.
Full story: https://getaibrief.com/story/ai-stocks-micron-selloff-june-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.